Slide 1

Slide 1 text

ABACBS short talk SVclone Inferring structural variant cancer cell fraction Supervisors: Chris Hovens, Niall Corcoran, Geoff Macintyre, Cheng-Soon Ong and Tony Papenfuss Marek Cmero, PhD Candidate – Dept. Surgery/CiS (Currently based at Murdoch Children’s Research Institute)

Slide 2

Slide 2 text

Cancer is an evolutionary process

Slide 3

Slide 3 text

Different cancers are driven by different types of mutations Source: Ciriello et al. 2013, doi:10.1038/ng.2762

Slide 4

Slide 4 text

chrA chrB Ref Donor Deletion Ref Donor Tandem duplication Ref Donor Translocation Ref Donor Interspersed duplication Ref Donor Inversion Inter-chromosomal translocation What is structural variation (SV)? Copy-number Aberrations (CNAs) Balanced rearrangements chrA chrB Ref Donor Deletion Ref Donor Tandem duplication Ref Donor Translocation Ref Donor Interspersed duplication Ref Donor Inversion Inter-chromosomal translocation Copy-number aberrations alone do not completely capture structural variation of cancer

Slide 5

Slide 5 text

Clonal analysis using whole-genome sequencing

Slide 6

Slide 6 text

Estimating clonal frequencies through VAF Calculating Variant Allele Frequency (VAF) TCTTCATTTGCAGCTAGTCGTGTGGGCTTAGT TCTTCATTTGCAGCTAGTCGTGTGGGCTTAGT TCTTCATTTGCAGCTAGTCGTGTGGGCTTAGT TCTTCATTTGCAGCTAGTCGTGTGGGCTTAGT TCTTCATTTGCAGCTAATCGTGTGGGCTTAGT TCTTCATTTGCAGCTAATCGTGTGGGCTTAGT TCTTCATTTGCAGCTAATCGTGTGGGCTTAGT TCTTCATTTGCAGCTAATCGTGTGGGCTTAGT TCTTCATTTGCAGCTAATCGTGTGGGCTTAGT TCTTCATTTGCAGCTAATCGTGTGGGCTTAGT Coverage = 10 A: 6 REF G: 4 SNV VAF = 4/10 = 40% REF: TCTTCATTTGCAGCTAATCGTGTGGGCTTAGT reads

Slide 7

Slide 7 text

Calculating VAF of structural variants Breakpoint Breakpoint

Slide 8

Slide 8 text

Inferring tumour evolution through VAFs # variants # variants # variants

Slide 9

Slide 9 text

SVclone pipeline Calculate VAFs Infer CCFs

Slide 10

Slide 10 text

SVclone validation # variants # variants # variants

Slide 11

Slide 11 text

Point mutation vs. structural variant in pan-cancer samples Enriched in neutral subclonal SVs Fraction of subclonal SVs Fraction of subclonal point mutations

Slide 12

Slide 12 text

Subclonal neutral rearrangement phenotype (SCNR)

Slide 13

Slide 13 text

Summary • SVclone fills the gap for clonal analysis of structural variants • In pan-cancer cohort, found tumour subtype enriched in subclonal neutral rearrangements (SCNR) with reduced overall survival

Slide 14

Slide 14 text

Acknowledgements The University of Melbourne/Royal Melbourne Hospital • *Dr. Christopher Hovens • *Dr. Niall Corcoran • Natalie Kurganovs • Stefano Mangiola • Kangbo Mo Cancer Research UK Cambridge Institute • *Dr. Geoffrey Macintyre • Dr. Florian Markowetz Data61/Australian National University • *Dr. Cheng-Soon Ong The Walter + Eliza Hall Institute • *Dr. Tony Papenfuss • Dr. Jan Schröder The University of Glasgow • Dr. Ke Yuan PCAWG Evolution and Heterogeneity Working Group (esp. Peter Van Loo, David Wedge and Stefan Dentro) People (*supervisors) Funding Thank you to Roger Riordan of the Cybec Foundation for his generous Urology Fellowship funding contribution Compute Advisory panel • Dr. HongJian Zhu, Dr. Andrew Lonie SVclone: https://github.com/mcmero/SVclone https://doi.org/10.1101/172486 (preprint)